[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 14, 1993


JAMA. 1993;270(2):265-266. doi:10.1001/jama.1993.03510020133048

Recent research results have produced new developments in the areas of prostate cancer and benign prostatic hyperplasia.

The American Cancer Society1 and the American Urological Association2 now recommend annual prostate-specific antigen (PSA) level testing and rectal examinations beginning at the age of 50 years for the early detection of prostate cancer, and beginning at the age of 40 years for high-risk men such as African Americans and those with a strong family history of prostate cancer. An upper age limit has not been set, but routine screening is not desirable in men with a life expectancy of less than 10 years. Annual examinations may be especially important in men who have had a vasectomy, who may have an increased risk of prostate cancer.3 Serial PSA level measurements over an extended period identify men with prostate cancer years before the disease becomes clinically manifest,4 and generally detect